Nanozymes: a new approach for leukemia therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Hematology

Background:

• Leukemia is a clonal hematopoietic stem cell disorder with impaired redox homeostasis.
• Reactive oxygen species (ROS) imbalance is a hallmark of leukemogenesis.
• Nanozymes offer enzyme-like catalytic activities to modulate ROS levels.

Purpose of the Study:

• To review recent advancements in nanozyme applications for leukemia therapy.
• To elucidate the mechanisms underlying nanozyme anti-leukemia efficacy.
• To discuss challenges and future prospects of nanozymes in leukemia treatment.

Main Methods:

• Literature review of studies on nanozymes targeting leukemia.
• Analysis of nanozyme catalytic activities (peroxidase, catalase, SOD, oxidase-like).
• Evaluation of in vitro and in vivo anti-leukemia effects of nanozymes.

Main Results:

• Nanozymes demonstrate significant potential in regulating ROS levels in leukemia cells.
• Various nanozymes exhibit promising anti-leukemia efficacy through diverse mechanisms.
• Nanozymes can overcome limitations of natural enzymes in therapeutic applications.

Conclusions:

• Nanozymes represent a promising therapeutic strategy for leukemia by modulating redox homeostasis.
• Further research is needed to address challenges and optimize nanozyme development for clinical translation.
• Nanozymes hold potential for synergistic antitumor therapy in leukemia treatment.